Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
November 24, 2008

Poniard Pharmaceuticals Taps Baxter Oncology for Commercial Supply of Picoplatin

  • Poniard Pharmaceuticals contracted with Baxter Oncology for the commercial manufacture and supply of injectable picoplatin drug product. Poniard is developing picoplatin, its lead product candidate, as a potential new platform product for the treatment of solid tumors. The company is evaluating picoplatin in four clinical trials, including an ongoing pivotal Phase III trial in small-cell lung cancer, Phase II trials in colorectal and prostate cancers, and a Phase I trial of an oral formulation.

    Earlier this year, Poniard entered into an agreement with W. C. Heraeus to manufacture picoplatin active pharmaceutical ingredient (API) and be ready to ship commercial quantities of picoplatin by 2009. Heraeus is the current manufacturer of picoplatin API for the company's four ongoing clinical trials.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: yourname@example.com An error has occurred. Please contact Customer Service at contactGEN@genengnews.com
  • You’re all set! Thank you for subscribing to GEN Highlights.